{"id":69609,"date":"2026-07-08T14:40:53","date_gmt":"2026-07-08T06:40:53","guid":{"rendered":"https:\/\/flcube.com\/?p=69609"},"modified":"2026-07-08T14:40:54","modified_gmt":"2026-07-08T06:40:54","slug":"astrazeneca-and-ionis-launch-wainua-eplontersen-in-china-for-hereditary-attr-amyloidosis-with-polyneuropathy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69609","title":{"rendered":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Wainua (eplontersen sodium injection)<\/strong>, jointly developed by <strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) and <strong>Ionis Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ: IONS<\/a>), was officially launched in China for the treatment of <strong>adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN)<\/strong>. The once-monthly <strong>gene-silencing agent<\/strong> received Chinese regulatory approval in <strong>December 2025<\/strong> based on positive results from the <strong>Phase III NEURO-TTRansform clinical trial<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-product-launch-amp-regulatory-background\" class=\"wp-block-heading\">Product Launch &amp; Regulatory Background<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Wainua (eplontersen sodium injection)<\/td><\/tr><tr><td><strong>Developers<\/strong><\/td><td>AstraZeneca plc \/ Ionis Pharmaceuticals<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN)<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Once-monthly subcutaneous injection<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>December 2025 (China)<\/td><\/tr><tr><td><strong>Launch Date<\/strong><\/td><td>8 July 2026 (China)<\/td><\/tr><tr><td><strong>Pivotal Trial<\/strong><\/td><td>Phase III NEURO-TTRansform<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Upstream inhibition of transthyretin (TTR) production<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-context-amp-therapeutic-innovation\" class=\"wp-block-heading\">Disease Context &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ATTRv-PN Disease Profile<\/strong>: A <strong>debilitating and fatal inherited disorder<\/strong> caused by mutations in the transthyretin (TTR) gene, leading to misfolded TTR protein accumulation in peripheral nerves and other organs. The disease primarily affects the <strong>peripheral nervous system<\/strong>, causing progressive sensorimotor neuropathy, autonomic dysfunction, and cardiac complications.<\/li>\n\n\n\n<li><strong>Gene-Silencing Mechanism<\/strong>: Wainua utilizes <strong>ligand-conjugated antisense oligonucleotide (LICA) technology<\/strong> to specifically target and degrade TTR mRNA in hepatocytes, reducing the production of both mutant and wild-type TTR protein at the source\u2014representing an <strong>upstream therapeutic approach<\/strong> compared to stabilizer therapies.<\/li>\n\n\n\n<li><strong>Clinical Differentiation<\/strong>: The <strong>once-monthly dosing regimen<\/strong> offers significant convenience advantages over more frequent administration schedules of competing therapies, potentially improving patient adherence and quality of life.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Hereditary ATTR amyloidosis affects an estimated <strong>10,000-15,000 patients in China<\/strong>, though significant underdiagnosis suggests the actual prevalence may be substantially higher, creating substantial unmet medical need.<\/p>\n\n\n\n<h2 id=\"h-commercial-strategy-amp-market-positioning\" class=\"wp-block-heading\">Commercial Strategy &amp; Market Positioning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dual-Company Partnership<\/strong>: The launch leverages <strong>AstraZeneca&#8217;s established commercial infrastructure<\/strong> in China and <strong>Ionis&#8217;s expertise in RNA-targeted therapeutics<\/strong>, combining global pharmaceutical reach with specialized genetic medicine capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Premium Pricing Strategy<\/strong>: As a <strong>first-in-class gene-silencing therapy<\/strong> for ATTRv-PN in China, Wainua is positioned for premium pricing consistent with other orphan disease therapies, supported by robust clinical efficacy data and convenient dosing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Diagnostic Partnerships<\/strong>: Successful market penetration will depend on improved disease awareness and diagnostic capabilities, with both companies likely investing in physician education and diagnostic support programs to identify undiagnosed patients.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-strategic-implications\" class=\"wp-block-heading\">Competitive Landscape &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Leadership<\/strong>: Wainua enters China&#8217;s ATTR market following the earlier launches of <strong>tafamidis<\/strong> (TTR stabilizer) and <strong>patisiran<\/strong> (siRNA therapy), but differentiates through its <strong>LICA technology platform<\/strong> and <strong>monthly dosing convenience<\/strong>.<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Commercial success would validate Ionis&#8217;s <strong>LICA platform<\/strong> in the Chinese market, potentially accelerating development of additional LICA-based therapies for other rare genetic disorders.<\/li>\n\n\n\n<li><strong>Orphan Drug Economics<\/strong>: The launch represents a strategic investment in China&#8217;s emerging orphan drug market, where regulatory incentives and premium reimbursement are creating viable commercial pathways for ultra-rare disease therapies.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding product launches, market opportunities, and commercial strategies. Actual results may differ due to market adoption rates, reimbursement decisions, competitive dynamics, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69612,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[130,1498,1497,4621],"class_list":["post-69609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-astrazeneca","tag-ionis-pharmaceuticals","tag-nasdaq-ions","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69609\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy\" \/>\n<meta property=\"og:description\" content=\"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69609\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T06:40:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T06:40:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy\",\"datePublished\":\"2026-07-08T06:40:53+00:00\",\"dateModified\":\"2026-07-08T06:40:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0806.webp\",\"keywords\":[\"AstraZeneca\",\"Ionis Pharmaceuticals\",\"NASDAQ: IONS\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69609#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69609\",\"name\":\"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0806.webp\",\"datePublished\":\"2026-07-08T06:40:53+00:00\",\"dateModified\":\"2026-07-08T06:40:54+00:00\",\"description\":\"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69609\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0806.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69609#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy - Insight, China&#039;s Pharmaceutical Industry","description":"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69609","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy","og_description":"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.","og_url":"https:\/\/flcube.com\/?p=69609","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T06:40:53+00:00","article_modified_time":"2026-07-08T06:40:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69609#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69609"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy","datePublished":"2026-07-08T06:40:53+00:00","dateModified":"2026-07-08T06:40:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69609"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69609#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","keywords":["AstraZeneca","Ionis Pharmaceuticals","NASDAQ: IONS","NYSE:\u202fAZN"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69609#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69609","url":"https:\/\/flcube.com\/?p=69609","name":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69609#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69609#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","datePublished":"2026-07-08T06:40:53+00:00","dateModified":"2026-07-08T06:40:54+00:00","description":"Wainua (eplontersen sodium injection), jointly developed by AstraZeneca plc (NYSE: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS), was officially launched in China for the treatment of adult patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). The once-monthly gene-silencing agent received Chinese regulatory approval in December 2025 based on positive results from the Phase III NEURO-TTRansform clinical trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69609#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69609"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69609#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","width":1080,"height":608,"caption":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69609#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69609"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69609\/revisions"}],"predecessor-version":[{"id":69613,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69609\/revisions\/69613"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69612"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}